Temple Lung Center at ATS 2026: Conference Recap

The American Thoracic Society's 2026 International Conference brought together leading voices in pulmonary, critical care, and sleep medicine — and Temple Health was well represented.

By
June 1, 2026
7 min

Temple Health

Overview

The American Thoracic Society's 2026 International Conference showcased advancements in pulmonary medicine, with Temple Lung Center presenting over 70 abstracts. Key findings included the efficacy of pegtarazimod in reducing supplemental oxygen needs in COPD and the impact of mepolizumab on exacerbation rates across diverse COPD populations.

Background

The American Thoracic Society's annual conference serves as a pivotal platform for sharing the latest research in pulmonary, critical care, and sleep medicine. This year's conference highlighted innovative therapeutic approaches and diagnostic strategies, emphasizing the importance of ongoing research in improving patient outcomes in lung diseases.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

Pegtarazimod demonstrated safety and reduced supplemental oxygen needs in acute COPD exacerbations.
Mepolizumab significantly reduced hospitalization risk for COPD exacerbations in patients with eosinophil counts starting from 150 cells/µL.
Elevated eosinophil counts near conception were associated with increased asthma exacerbations during pregnancy.
Baseline 6-minute walk test heart rate metrics correlated with greater hospital utilization in moderate-to-severe COPD patients.
Inhaled treprostinil preserved lung function in adults with idiopathic pulmonary fibrosis (IPF).
Disparities in survival after lung transplant for SARD-ILD were noted based on race and ethnicity.